OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/EGFR
Lung Cancer — Non-Small Cell (NSCLC)EGFR Clinical Trials
EGFR mutations — primarily exon 19 deletions and exon 21 L858R substitutions — drive tumor growth in about 15% of non-squamous NSCLC in Western populations and up to 50% in East Asian populations. Osimertinib, a third-generation EGFR inhibitor, is the current first-line standard for advanced disease and the approved adjuvant standard after resection (ADAURA). Trials investigate novel EGFR inhibitors, antibody-drug conjugates, and strategies to overcome on-target resistance mutations such as C797S.
Top recruiting EGFR Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 183 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Merck Sharp & Dohme LLC
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology, Inc.